Rhenu Buller, an expert on disruptive technologies at business consultancy Frost & Sullivan's Asia Pacific office, outlines the technological…

Kevin Rufang Huang is the president and founder of the Chinese Organization for Rare Disorders (CORD). A rare disease patient himself, he is…

Drug development in rare diseases is currently in a very exciting time. While much of the focus is on the scientific advances,  access to rare…

Min-Young Kim, general manager at Ipsen Korea discusses her strategy to refocus the Korean affiliate away from the toxin market and towards oncology…

Long regarded as a neglected backwater within the drug discovery landscape and the preserve of only a handful of niche players, the rare disease space…

The 28th February 2019, marks the twelfth international Rare Disease Day. On and around this day hundreds of patient organisations from countries and…

Following on from Johnson & Johnson’s acquisition of Actelion in January 2017 and Takeda’s takeover of Shire two years later, pharma…

This week the Korean Ministry of Food and Drug Safety announced that as of 12th March 2019 a revised narcotics bill will go into effect that will…

The Top 10 bestselling orphan drugs in the USA in 2017. Celgene's Revlimid (generic name lenolidamide) leads the way with sales of USD 5.4 billion,…

The top 10 companies in the world ranked by global orphan drug sales and market share in 2017. Swiss giants Novartis and Roche take the top two…

In the run-up to Rare Disease Day 2019, David H. Crean, PhD, Managing Director for Objective Capital Partners, reviews the investment and deal…

Durhane Wong-Rieger is the President & CEO of the Canadian Organization for Rare Disorders (CORD). In her first article for PharmaBoardroom,…